Cargando...
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies
BACKGROUND: Pre-exposure prophylaxis (PrEP) using antiretroviral (ARV) agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly variable, which is thought to be largely due to the...
Gardado en:
| Publicado en: | J Acquir Immune Defic Syndr |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5123706/ https://ncbi.nlm.nih.gov/pubmed/27792681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001119 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|